Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers

Summary

This will be a randomized, double-blind, placebo-controlled, dose-escalation study of 3 dose levels of LMN-101. Healthy volunteers will take LMN-101 or placebo orally either as a single dose or at one of three dose levels three times daily over 28 days. Protocol-specified evaluations and procedures will be performed on Days 1-2 and every one-two weeks during dosing. Study observation will continue until 4 weeks after the last dose of study drug.

Timeline

Start

2019-11-15

Primary completion

2020-04-15

Completion

2020-06-24

Drugs

Indications